Tag Archives: Pharmacy & Medical Research (TRBC level 2)

Amazon, the pharmaceutical company must help the COVID-19 vaccine reach the poorest: the German minister | Instant News


FILE PHOTO: German Minister for Economic Cooperation and Development Gerd Mueller attends a weekly cabinet meeting at the Chancellor in Berlin, Germany 16 September 2020. Michael Sohn / Pool via REUTERS

BERLIN (Reuters) – Companies benefiting from the coronavirus crisis, such as Amazon and drugmakers, should join wealthy nations in helping to fund vaccine access for poor countries, Germany’s international development minister said Tuesday.

A massive research effort has seen several promising vaccines reach approval thresholds in recent weeks. But with rich countries ordering supplies, concerns have grown that poor countries will fall behind.

Gerd Mueller, Germany’s development minister, said it shouldn’t just be richer governments trying to ensure the developing world gets its fair share.

“Private companies that have benefited the most from the coronavirus crisis, such as Amazon or pharmaceutical companies, also have an obligation,” he told Reuters.

On Sunday, German Chancellor Angela Merkel said she was concerned that not enough was being done to ensure adequate supplies of the new vaccine were made available to poorer states, even as European and United States governments cut supplies.

Pharmaceutical companies should offer the World Health Organization’s COVAX initiative – designed to provide supplies to poorer countries – “the best conditions and a good price” for their vaccines, Mueller said.

Reporting by Andreas Rinke, written by Thomas Escritt, editing by Mark Potter

.



image source

Brazil has enough infection data to analyze the COVID-19 Sinovac vaccine – officials | Instant News


FILE PHOTO: A man works at the packaging facility of Chinese vaccine maker Sinovac Biotech, developing an experimental coronavirus disease (COVID-19) vaccine, during a government-organized media tour in Beijing, China, September 24, 2020. REUTERS / Thomas Peter / File Photo

SAO PAULO (Reuters) – Brazil has gathered enough infection data from the final-stage trial of the experimental COVID-19 vaccine developed by China’s Sinovac Biotech and expects interim results on its efficiency in early December, trial organizers said on Monday.

Dimas Covas, director of the Butantan biomedical research institute which is running the final-stage trial of the Sinovac vaccine in Brazil, said it now has 74 confirmed cases among the trial participants, above the 61 initial milestones set for an interim efficiency analysis.

He said the independent committee is likely to release efficiency results in the first week of December based on its data analysis.

The news comes as Britain’s AstraZeneca Plc on Monday joined US rivals Pfizer and Moderna and Russia in announcing positive results in a landmark trial, raising hopes that the world will soon have a successful vaccine to end the pandemic.

Covas said Brazil’s health ministry now had all the information needed to include Coronavac in the national program, while São Paulo’s Health Secretary Jean Gorinchteyn expected on Monday Brazilian regulators to approve the use of Sinovac’s vaccine, CoronaVac, in January.

João Gabbardo, head of Sao Paulo’s COVID-19 contingency committee, said at the same event that he expected China’s health regulators to approve Sinovac’s CoronaVac in December, which could speed up approval in Brazil.

The Sinovac vaccine has been promoted by Sao Paulo’s governor João Doria, a move that has put him at odds with President Jair Bolsonaro who is deeply skeptical of China.

Bolsonaro has attacked the Chinese vaccine for lacking credibility and it remains unclear whether the federal government will include it in its national inoculation program.

The ministry said on Sunday that it plans to sign a non-binding letter of intent to purchase vaccines from Pfizer Inc, Bharat Biotech India, Russia’s Direct Investment Fund, Moderna Inc and Janssen, a Johnson & Johnson unit, but did not mention Sinovac’s. candidate.

Reporting by Eduardo Simoes and Anthony Boadle, written by Stephen Eisenhammer; Edited by Bernadette Baum, Miyoung Kim & Shri Navaratnam

.



image source

Brazil has enough infection data to analyze the COVID-19 Sinovac vaccine – officials | Instant News


FILE PHOTO: A man works at the packaging facility of Chinese vaccine maker Sinovac Biotech, developing an experimental coronavirus disease (COVID-19) vaccine, during a government-organized media tour in Beijing, China, September 24, 2020. REUTERS / Thomas Peter / File Photo

SAO PAULO (Reuters) – Brazil has gathered enough infection data from the final-stage trial of the experimental COVID-19 vaccine developed by China’s Sinovac Biotech and expects interim results on its efficiency in early December, trial organizers said on Monday.

Dimas Covas, director of the Butantan biomedical research institute which is running the final-stage trial of the Sinovac vaccine in Brazil, said it now has 74 confirmed cases among the trial participants, above the 61 initial milestones set for an interim efficiency analysis.

He said the independent committee is likely to release efficiency results in the first week of December based on its data analysis.

The news comes as Britain’s AstraZeneca Plc on Monday joined US rivals Pfizer and Moderna and Russia in announcing positive results in a landmark trial, raising hopes that the world will soon have a successful vaccine to end the pandemic.

Covas said Brazil’s health ministry now had all the information needed to include Coronavac in the national program, while São Paulo’s Health Secretary Jean Gorinchteyn expected on Monday Brazilian regulators to approve the use of Sinovac’s vaccine, CoronaVac, in January.

João Gabbardo, head of Sao Paulo’s COVID-19 contingency committee, said at the same event that he expected China’s health regulators to approve Sinovac’s CoronaVac in December, which could speed up approval in Brazil.

The Sinovac vaccine has been promoted by Sao Paulo’s governor João Doria, a move that has put him at odds with President Jair Bolsonaro who is deeply skeptical of China.

Bolsonaro has attacked the Chinese vaccine for lacking credibility and it remains unclear whether the federal government will include it in its national inoculation program.

The ministry said on Sunday that it plans to sign a non-binding letter of intent to purchase vaccines from Pfizer Inc, Bharat Biotech India, Russia’s Direct Investment Fund, Moderna Inc and Janssen, a Johnson & Johnson unit, but did not mention Sinovac’s. candidate.

Reporting by Eduardo Simoes and Anthony Boadle, written by Stephen Eisenhammer; Edited by Bernadette Baum, Miyoung Kim & Shri Navaratnam

.



image source

Brazil signed a letter of intent to purchase five COVID vaccines | Instant News


FILE PHOTOS: Medical personnel treating patients in the intensive care unit (ICU) of Nossa Senhora da Conceicao hospital, during the coronavirus disease (COVID-19) outbreak, in Porto Alegre, Brazil, 19 November 2020. REUTERS / Diego Vara / File Photo

BRASILIA (Reuters) – Brazil’s health ministry said on Sunday it would sign a non-binding letter of intent to buy a coronavirus vaccine from four companies and Russia’s state wealth fund, adding that any purchase would be subject to approval by state regulators.

According to the ministry, officials met last week with representatives of Pfizer Inc, Bharat Biotech India, Russia’s Direct Investment Fund, Moderna Inc and Janssen, a unit of Johnson & Johnson.

In a statement, the ministry said its legal and technical departments were analyzing documents presented by the five entities and determining how best to purchase the vaccine at “the right time”.

The government has a contract to guarantee access to 142,900,000 doses of the coronavirus vaccine, enough to immunize at least a third of Brazil’s population, officials said in the statement.

So far, the Brazilian federal government’s main bet is on the vaccine developed by AstraZeneca PLC, which has signed a supply contract.

In Sao Paulo, Brazil’s largest state, local authorities have signed an agreement with China Sinovac Biotech Ltd to test and produce vaccines locally. Brazilian President Jair Bolsonaro, a long-time critic of China, has dismissed the vaccine as untrustworthy, without providing evidence.

Reporting by Marcela Ayres; Written by Gram Slattery

.



image source

Bharat Biotech offers a potential Brazilian COVID-19 vaccine | Instant News


FILE PHOTO: A man rides his motorbike past a bus parked by Indian biotech firm Bharat Biotech outside its offices in Hyderabad, India, July 3, 2020. REUTERS / Stringer / File Photo

BRASILIA (Reuters) – Bharat Biotech India this week offered a COVID-19 vaccine to Brazil that is in its final stage of clinical trials and a possible technology transfer partnership, a company executive said on Friday.

A private pharmaceutical company based in the southern city of Hyderabad is developing a whole virion inactivated vaccine called Covaxin that could be licensed in the second quarter of 2021.

“The data looks very good in terms of both reduction and prevention of disease, and we are starting Phase 3 clinical trials this week,” Executive Director Sai Prasad told Reuters.

Bharat Biotech is currently recruiting 26,000 volunteers in India for trials and results are expected between March and April, he said.

Pfizer Inc said on Wednesday that it had offered to provide Brazil with millions of doses of the COVID-19 vaccine in the first half of 2021, amid evidence that the coronavirus is spreading faster in South America’s largest country.

Pfizer and German partner BioNTech SE report the results of recent trials showing the vaccine is 95% effective in preventing COVID-19.

Bharat Biotech representatives met this week with Brazil’s health ministry and regulatory agency officials to see what are the requirements for vaccine licensing in Brazil and whether trials should take place there as well.

“We are very open to partnerships and technology transfer,” Prasad said in an interview from Hyderabad.

Bharat Biotech has sold a Hepatitis B vaccine to Brazil and is developing another vaccine for Zika and Chicungunya that the South American country is interested in, he said.

Reporting by Anthony Boadle; Edited by Nick Macfie

.



image source